Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluphenazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.98 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 1.00 |
| ▸ | RAD52 | P43351 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 3/20 | 1.00 |
| ▸ | GMNN | O75496 | 3/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | UBE2N | P61088 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluphenazine SCHEMBL2560022 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29860638 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL30390918 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL41635 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL41634 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL7194249 | 0.99 | LMNA (0.98) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29388890 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL29354183 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL5072860 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 | |
| Fluphenazine SCHEMBL19221 | 0.99 | LMNA (1.00) | LMNAMAPTSMN1; SMN2NPSR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2494865-A2 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME | Aeon Medix Inc. (KR) | 2012-09-05 | — | — | EP | claimed |
| WO-2011027971-A2 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME | 주식회사이언메딕스 (KR) | 2011-03-10 | — | — | WO | claimed |
| EP-2484752-B1 | EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF | YUNGJIN PHARMACEUTICAL CO LTD (KR) | 2016-09-21 | — | — | EP | disclosed |
| US-9274109-B2 | Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same | AEON MEDIX INC. (KR) | 2016-03-01 | — | — | US | disclosed |
| US-9273359-B2 | Extracellular vesicles derived from Gram-positive bacteria, and use thereof | YUNGJIN PHARM. CO., LTD. (KR) | 2016-03-01 | — | — | US | disclosed |
| US-9201072-B2 | Gut flora-derived extracellular vesicles, and method for searching for a disease model, vaccine, and candidate drug and for diagnosis using the same | AEON MEDIX INC. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-20150232934-A1 | EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF | AEON MEDIX INC. (KR) | 2015-08-20 | — | — | US | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8969653-B2 | Extracellular vesicles derived from gram-positive bacteria, and use thereof | AEON MEDIX INC. (KR) | 2015-03-03 | — | — | US | disclosed |
| EP-2494865-A2 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME | Aeon Medix Inc. (KR) | 2012-09-05 | — | — | EP | disclosed |
| US-20120222142-A1 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING THE SAME | AEON MEDIX INC. (KR) | 2012-08-30 | — | — | US | disclosed |
| EP-2484752-A2 | EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF | Aeon Medix Inc. (KR) | 2012-08-08 | — | — | EP | disclosed |
| US-20120159658-A1 | EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF | AEON MEDIX INC. (KR) | 2012-06-21 | — | — | US | disclosed |
| WO-2011027990-A9 | EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF | 주식회사이언메딕스 (KR) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011027971-A2 | GUT FLORA-DERIVED EXTRACELLULAR VESICLES, AND METHOD FOR SEARCHING FOR A DISEASE MODEL, VACCINE, AND CANDIDATE DRUG AND FOR DIAGNOSIS USING SAME | 주식회사이언메딕스 (KR) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011027990-A2 | EXTRACELLULAR VESICLES DERIVED FROM GRAM-POSITIVE BACTERIA, AND USE THEREOF | 주식회사이언메딕스 (KR) | 2011-03-10 | — | — | WO | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |